WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2007076422) ANTIBODIES AGAINST INTERLEUKIN-22 BINDING PROTEIN AND ITS USES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/076422    International Application No.:    PCT/US2006/062450
Publication Date: 05.07.2007 International Filing Date: 21.12.2006
Chapter 2 Demand Filed:    30.11.2007    
IPC:
C07K 16/00 (2006.01), A61K 45/00 (2006.01)
Applicants: DHY & CO., LTD [--/--]; Portcullis TrustNet Chambers, Road Town, Tortola (VG) (For All Designated States Except US).
HUANG, Yu Liang [US/US]; (US) (For US Only).
CHEN, Xu Wen [CN/CN]; (US) (For US Only).
HUANG, Zhi Hua [CN/CN]; (US) (For US Only)
Inventors: HUANG, Yu Liang; (US).
CHEN, Xu Wen; (US).
HUANG, Zhi Hua; (US)
Agent: LUI, Jacqueline; Eagle IP Ltd., 1201, 12/F, Kwai Hung Holdings Centre, 89 King's Road, Hong Kong (CN)
Priority Data:
60/752,397 22.12.2005 US
Title (EN) ANTIBODIES AGAINST INTERLEUKIN-22 BINDING PROTEIN AND ITS USES
(FR) ANTICORPS CONTRE LA PROTEINE DE LIAISON INTERLEUKINE 22 ET SON UTILISATION DANS LE TRAITEMENT DE TROUBLES METABOLIQUES
Abstract: front page image
(EN)The present invention relates to antibodies and antigen-binding fragments that bind to interleukin-22 binding protein, in particular, human interleukin-22 binding protein (IL-22 BP), and are involved in regulating interleukin-22-associated biological responses. The invention also relates to methods of using the antibodies and antigen-binding fragments to treat disorders associated with interleukin-22. The antibodies disclosed herein are useful in diagnosing, preventing, or treating metabolic disorders including obesity, diabetes, hyperlipidemia and hyperinsulinemia etc.
(FR)La présente invention concerne des anticorps et des fragments de liaison à l’antigène qui lient à la protéine de liaison interleukine-22, en particulier, cette même protéine humaine (IL-22 BP) ; ils participent à l’activité régularisante des réponses biologiques associées à l'interleukine 22. L'invention a aussi trait à des procédés d'utilisation des anticorps et des fragments de liaison à l'antigène permettant de traiter les troubles associés à l'interleukine 22. Les anticorps présentés ici sont utiles dans le diagnostic, la prévention ou le traitement de troubles métaboliques y compris l'obésité, le diabète, l'hyperlipidémie, l'hyperinsulinémie, etc.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)